Umifenovir (131707-23-8) is a broad-spectrum antiviral medication.1 It has shown activity against influenza A,B,and C, respiratory syncytial, SARS-CoV, adeno, parainfluenza type 5, polio, rhino, coxsackie, hanta, chikungungya, hepatitis B and C viruses.2,3 It blocks hemagglutinin-mediated membrane fusion of influenza virus particles.2 Umifenovir has recently been shown to inhibit SARS-CoV2 infection by blocking virus entry as well as release from endolysosomes during intracellular trafficking.5 It has been suggested that Umifenovir may block trimerization of the spike glycoprotein, a key step in host cell adhesion.6